Lymphoma / Leukemia / Myeloma News From Medical News Today
Thu, 02 Sep 2010 18:53:23 +0200
Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed Ph+ CML
The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...
Thu, 02 Sep 2010 03:00:00 PDT
Taking Aim At Pre-Leukemia Disorders: NewYork-Presbyterian/Columbia Establishes Myelodysplastic Syndromes Center
NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation. Myelodysplastic syndromes (MDS) are disorders interfering with blood production in the bone marrow...
Tue, 31 Aug 2010 01:00:00 PDT
LFB's Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In The USA For Chronic Lymphocytic Leukemia
The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010. Chronic lymphocytic leukemia is the most common form of leukemia in the United States...
Fri, 27 Aug 2010 01:00:00 PDT
NICE Proposes To Restrict Access To Velcade(R) In Newly Diagnosed Multiple Myeloma Patients Janssen-Cilag To Challenge NICE Recommendation
Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma...
Fri, 27 Aug 2010 01:00:00 PDT
NICE Draft Guidance Recommends Bortezomib And Thalidomide For Multiple Myeloma
In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate...
Thu, 26 Aug 2010 06:00:00 PDT
CAS Chemistry Research Report, A Decade Later Human Genome Discoveries Spur Growth Of Cancer Treatments
Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information...
Wed, 25 Aug 2010 02:00:00 PDT
Extensive Trial Confirms Benefits Of Early Steroid Withdrawal For Transplant Patients
A University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids...
Wed, 25 Aug 2010 00:00:00 PDT
EpiCept Corporation Receives Refusal To File Letter From US FDA On Ceplene New Drug Application
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene® (histamine dihydrochloride)...
Tue, 24 Aug 2010 00:00:00 PDT
Lawrence Medical Products Launches MoveAround™ IV Buggy For Kids - Toddler Age To Teen - Undergoing IV Therapy
Lawrence Medical Products, a family-owned business conceived to help Autumn Lawrence, diagnosed with infant leukemia in 2005 at seven and a half months old, has announced the launch of the MoveAround™ IV Buggy...
Thu, 19 Aug 2010 01:00:00 PDT
Link Between Blood Stem Cell And Leukemia Illuminated In UCSF-Led Study
A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop...
Wed, 18 Aug 2010 00:00:00 PDT
|
